9 results
The main objective is to investigate the role of MRs in memory acquisition and recall during stress and non-stress conditions. Specifically, we are interested in two domains of memory, spatial and fear memory. Secondary objectives are to determine…
Primary: To evaluate the safety and tolerability of LY3045697 after multiple oral dosing in healthy subjectsSecondary: To investigate the pharmacokinetics of LY3045697 after multiple oral dosing in healthy subjects
Comparison of the additional blood pressure lowering effect of RFSD with that of the addition of spironolactone in patients with a persistant increased blood pressure despite treatment with three different antihypertensive agents.
The primary objective of this study is to investigate the role of the MR in memory performance under stressful and non-stressful conditions in humans. More specifically the following question will be answered: What effects does the MR antagonist…
1. to study the effect of spironolacton and triamterene on blood pressure in anuric hemodialysis patients.2. to study the effect of treatment on body weight, serum elektrolytes, 24-hours sodium excretion, plasma aldosterone and renin concentrations…
Main objective: To investigate whether spironolactone can favourably alter extra-cellular matrix remodelling, assessed by changes in the fibrosis biomarker Procollagen Type III N-Terminal Peptide (PIIINP), in patients at increased risk of developing…
The first objective is to investigate whether biofeedback on HRV and voice volume will lead to a larger decrease of IPV compared to treatment as usual (CBT only). Second, to test the premise that IPV perpetrators have trouble self-observing bodily…
1) To compare pembrolizumab plus olaparib to abiraterone acetate or enzalutamide with respect to overall survival (OS)2) To compare pembrolizumab plus olaparib to abiraterone acetate or enzalutamide with respect to radiographic progression-free…
The primary objective of the SPIRIT*HF study is to compare Spironolactone to Placebo in reducing the rate…